About Us

Women's Cancer Initiative - Tata Memorial Hospital and Nag Foundation Invites you for the "4th edition of Year in Review: Breast Cancer Conference". This conference will be held on Sat 19th Jan - Sun 20th Jan 2019, at Hotel ITC Grand Central, Parel, Mumbai.

Breast cancer is not so much a disease as a universe - endlessly complex, huge and continuously evolving. Every year a large number of clinical, translational and basic studies are presented at many conferences, at least some of which have an impact on practice. It is becoming increasingly difficult for even specialized oncologists to keep pace with this explosion. Number of meetings in Best of format now try to make this information digestible to practicing clinicians.

As you are aware our conference aims at recapitulate the best breast cancer science every year in a Year in Review format. The theme of the meeting is ‘Breast Cancer: The Year That Was…2018’. For last few years this conference has established it identity of presenting best original scientific abstracts and deliberations covered in the major oncology conferences that took place in the preceding year. The scientific committee every year reviews original articles published in over 25 important oncology journals which also features in the scientific program. We strive to recapitulate the best original science presented at the following conferences of the immediately preceding year:

  • AACR (Annual meeting of American Association for Cancer Research)
  • ASCO (Annual meeting of American Society of Clinical Oncology)
  • ESMO (Annual meeting of European Society for Medical Oncology)
  • SABCS (San Antonio Breast Cancer Symposium)
  • ASTRO (Annual meeting of American Society for Radiation Oncology)
  • ESTRO (Annual meeting of European Society for Radiotherapy and Oncology)
  • St. Gallen Breast Cancer Conference
  • ESO-ESMO ABC4 (ESO-ESMO Advanced Breast Cancer)
  • COBRCA (Controversies in Breast Cancer)
  • Milan Breast Cancer Conference
  • ABS (Annual meeting of Association of Breast Surgery)
  • ASBS (Annual meeting of American Society of Breast Surgeons)

The meeting will be broadly classified in the following sessions:

  • Loco-regional therapy
  • Estrogen receptor positive disease
  • HER2 positive disease
  • Triple Negative Breast Cancer
  • Translational science
  • State-of-the-Science talk(s)
  • Rapid review session
  • Debates
  • Key Notes

In the above sessions, we intend to cover surgical, radiation, medical, pathology, biomarkers and imaging issues making this meeting a truly multi-disciplinary one. At the end of every session there will be rapid review presentation on additional abstracts. The selection of abstracts is based on originality, innovation and potential impact on clinical practice.

We believe that presentation of the most impactful and important abstracts from all important conferences in the preceding year will give the participants a feel of the landscape of breast cancer research, especially that impacts practice.

Research, especially those impacting our practice. For your reference, the meeting proceedings of the 1st, 2nd and 3rd Year in Review Conference is fully archived on www.yearinreview.in

We hope to benefit from your partnership and wisdom in initiating, undertaking and nurturing this idea.

With best wishes

Organizing Chairperson:

Dr. Sudeep Gupta
Professor of Medical Oncology
Tata Memorial Centre

Dr. Shona Nag
Consultant Medical Oncologist
Jehangir Hospital

Scientific Program 2016

Scientific Program 2017

Scientific Program 2018

Scientific Program 2019

    Coming Soon ...!

Dr. Hope Rugo, USA

Dr. Hope Rugo is a medical oncologist and hematologist specializing in breast cancer research and treatment. A Clinical Professor of Medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at UCSF in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer. She entered the field of breast cancer in order to incorporate novel therapies based on an understanding of the biology of cancer with excellent quality of care into the treatment of women with breast cancer.

Dr. Rugo is the Director of the Breast Oncology Clinical Trials Program, and is the principal investigator of multiple clinical trials focusing on combining novel targeted therapeutics with standard treatment to improve the treatment of both early and late stage breast cancer. In addition, Dr. Rugo is working on studies to evaluate cognitive function in women receiving chemotherapy for breast cancer, as well as novel ways to reduce toxicity from therapy. Dr. Rugo has established collaborations with a number of other large academic medical centers for the purpose of expanding the novel therapies that are available for our patients, including herbal agents that appear to have an antitumor effect in the laboratory. She is an active member of the national cooperative group, CALGB, and a is a founding member of the Breast Cancer Research Consortium, as well as serving as an investigator in the UCSF Breast SPORE (the Bay Area Specialized Program of Research Excellence in Breast Cancer). Dr. Rugo teaches medical students and physicians, and regularly lectures locally, nationally and internationally on subjects relating to the treatment of breast cancer. At UCSF, Dr. Rugo runs the Breast Forum, an open bimonthly evening educational session for breast cancer patients, families and friends from throughout the bay area.

Dr. Rugo graduated from the University of Pennsylvania School of Medicine in 1983. She completed a residency in internal medicine and primary care followed by a fellowship in hematology and oncology at the University of California San Francisco. She was a postdoctoral fellow in immunology participating in laboratory research at Stanford University from 1988-1990. In 1990, Dr. Rugo joined the faculty at UCSF in the Division of Hematology and Oncology. Dr. Rugo has been recognized for her excellence in both patient care and in teaching of both medical students and training physicians. She has received several awards including the Bank of America Gianini Foundation Award and a UCSF Clinical Cancer Center Investigator Research Program intra-mural award. In 2006, she was honored for her work in Breast Cancer Research by the Friends of the Breast Care Center.

Dr. Shaheenah Dawood, Dubai

Dr. Shaheenah Dawood is the Head of Medical Oncology and the Head of the Breast Cancer Program at Dubai Hospital in the United Arab Emirates. Dr. Dawoodcompleted her M.B.B.Ch at Dubai Medical College in 1998 and a Master of Public Health degree at the Harvard School of Public Health, Boston, USA in 2008. Her postgraduate medical training programs include a Fellowship at McGill University in Canada in 2006, and the Susan Komen Breast Cancer Fellowship at the University of Texas M.D. Anderson Cancer Center in 2007.

Dr. Dawood is a member of various professional organizations, including the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR), the Canadian Association of Medical Oncologists, the Emirates Medical Association, and the Inflammatory Breast Cancer Research Group. She is also the co-director of the Middle East Research Network.

Dr. Dawood has been a primary author or collaborator on over 50 peer-reviewed publications in national and international journals. In addition, she has collaborated with other authors to write a number of book chapters. Dr. Dawood has also been involved as a journal reviewer and as an editorial consultant for many cancer-related journals.

Research Interests: Dr. Dawood’s researcher interests encompass Triple Negative Breast Cancer, Inflammatory Breast Cancer, Metastases, as well as life-style issues and survival outcome of cancer patients.

Dr.Chris Twelves

Chris Twelves is Professor of Clinical Cancer Pharmacology and Oncology in the Leeds Institute of Cancer and Pathology (LICAP) at the University of Leeds and Honorary Consultant in Oncology at Leeds Teaching Hospitals.

His first degree was in Pharmacology and Experimental Medicine before qualifying in Medicine and training as a medical oncologist with a particular interest in new drug development and clinical pharmacology; his clinical practice has been in colorectal and breast cancer. Professor Twelves’ has been directly involved in the development of several important cancer drugs.

Professor Twelves also heads the Experimental Cancer Medicine Centre in Leeds and is Head of Section of Oncology and Clinical Research at the Leeds Cancer Research UK Centre

Professor Twelves has published over 200 papers in journals including the New England Journal of Medicine, Lancet and Journal of Clinical Oncology and spoken at numerous international meetings. He has also edited, or contributed to, several books including one on Phase I clinical trials and another on the design of Phase II clinical trials.

We will get back soon......!